Barbara Domayne-Hayman

Barbara has 30 years’ experience in the life sciences industry, with the first 11 years on the commercial side of a large organisation (ICI/Zeneca/AstraZeneca), after which she transitioned to the entrepreneurial world of biotech and emerging companies.

She has worked in a wide range of biotechs, including both therapeutic product and platform technology companies, working in business development, as CEO and in non-exec roles including Chair.

Barbara has been involved in a number of major strategic transactions and fundraising, but her main focus is on helping to build companies. She is also on the Cambridge Enterprise Seed Investment Committee.